Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at ...

Health CanadaIn Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment ...

In Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment is unaffordable. Canadians deserve a health care system that provides timely access to quality ...

In the study, 69 patients with cutaneous T-cell lymphoma, including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days.

The first step in this bilateral agreement will be to deliver funding to support the province for the following four drugs under the National Strategy for Drugs for Rare Diseases: Poteligeo, for the ...

for the treatment of mycosis fungoides or Sézary syndrome; Oxlumo, for the treatment of hyperoxaluria type 1; and Epkinly, for relapsed or refractory diffuse large B-cell lymphoma. “By ...